265 related articles for article (PubMed ID: 17914897)
1. BP goal achievement in patients with uncontrolled hypertension : results of the treat-to-target post-marketing survey with irbesartan.
Schrader J; Bramlage P; Lüders S; Thoenes M; Schirmer A; Paar DW
Clin Drug Investig; 2007; 27(11):783-96. PubMed ID: 17914897
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and tolerability of olmesartan medoxomil in patients with mild to moderate essential hypertension: the OLMEBEST Study.
Barrios V; Boccanelli A; Ewald S; Girerd X; Heagerty A; Krzesinski JM; Lins R; Rodicio J; Stefenelli T; Woittiez A; Böhm M
Clin Drug Investig; 2007; 27(8):545-58. PubMed ID: 17638395
[TBL] [Abstract][Full Text] [Related]
3. Antihypertensive efficacy and tolerability of irbesartan/hydrochlorothiazide in hypertensive patients stratified by body mass index and type 2 diabetes mellitus status: a post hoc subgroup analysis of the Irbesartan/HCTZ Blood Pressure Reductions in Diverse Patient Populations trial.
Lewin AJ; Weir MR
Clin Ther; 2008 Dec; 30(12):2354-65. PubMed ID: 19167594
[TBL] [Abstract][Full Text] [Related]
4. Irbesartan/hydrochlorothiazide for the treatment of isolated systolic hypertension: a subgroup analysis of the INCLUSIVE trial.
Chrysant SG; Neutel JM; Ferdinand KC;
J Natl Med Assoc; 2009 Apr; 101(4):300-7. PubMed ID: 19397219
[TBL] [Abstract][Full Text] [Related]
5. Irbesartan for the treatment of hypertension in patients with the metabolic syndrome: a sub analysis of the Treat to Target post authorization survey. Prospective observational, two armed study in 14,200 patients.
Kintscher U; Bramlage P; Paar WD; Thoenes M; Unger T
Cardiovasc Diabetol; 2007 Apr; 6():12. PubMed ID: 17407587
[TBL] [Abstract][Full Text] [Related]
6. A comparison of the efficacy and safety of irbesartan/hydrochlorothiazide combination therapy with irbesartan monotherapy in the treatment of moderate or severe hypertension in diabetic and obese hypertensive patients: a post-hoc analysis review.
Neutel JM
Postgrad Med; 2011 Jul; 123(4):126-34. PubMed ID: 21680997
[TBL] [Abstract][Full Text] [Related]
7. Antihypertensive efficacy of Irbesartan/HCTZ in men and women with the metabolic syndrome and type 2 diabetes.
Sowers JR; Neutel JM; Saunders E; Bakris GL; Cushman WC; Ferdinand KC; Ofili EO; Weber MA;
J Clin Hypertens (Greenwich); 2006 Jul; 8(7):470-80. PubMed ID: 16849900
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of fixed combinations of irbesartan/hydrochlorothiazide in older vs younger patients with hypertension uncontrolled with monotherapy.
Cushman WC; Neutel JM; Saunders E; Bakris GL; Ferdinand KC; Ofili EO; Sowers JR; Madder R; Weber MA
Am J Geriatr Cardiol; 2008; 17(1):27-36. PubMed ID: 18174757
[TBL] [Abstract][Full Text] [Related]
9. Fixed-dose combination of zofenopril plus hydrochlorothiazide vs. irbesartan plus hydrochlorothiazide in hypertensive patients with established metabolic syndrome uncontrolled by previous monotherapy. The ZAMES study (Zofenopril in Advanced MEtabolic Syndrome).
Napoli C; Omboni S; Borghi C;
J Hypertens; 2016 Nov; 34(11):2287-97. PubMed ID: 27653164
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of fixed combinations of irbesartan/hydrochlorothiazide in hypertensive women: the inclusive trial.
Ofili EO; Cable G; Neutel JM; Saunders E
J Womens Health (Larchmt); 2008; 17(6):931-8. PubMed ID: 18681815
[TBL] [Abstract][Full Text] [Related]
11. The efficacy and safety of low- and high-dose fixed combinations of irbesartan/hydrochlorothiazide in patients with uncontrolled systolic blood pressure on monotherapy: the INCLUSIVE trial.
Neutel JM; Saunders E; Bakris GL; Cushman WC; Ferdinand KC; Ofili EO; Sowers JR; Weber MA;
J Clin Hypertens (Greenwich); 2005 Oct; 7(10):578-86. PubMed ID: 16227760
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of irbesartan/HCTZ in severe hypertension according to cardiometabolic factors.
Franklin SS; Neutel JM
J Clin Hypertens (Greenwich); 2010 Jul; 12(7):487-94. PubMed ID: 20629810
[TBL] [Abstract][Full Text] [Related]
13. A home blood pressure monitoring study comparing the antihypertensive efficacy of two angiotensin II receptor antagonist fixed combinations.
Bobrie G; Delonca J; Moulin C; Giacomino A; Postel-Vinay N; Asmar R;
Am J Hypertens; 2005 Nov; 18(11):1482-8. PubMed ID: 16280286
[TBL] [Abstract][Full Text] [Related]
14. Once-daily fixed-combination irbesartan 300 mg/ hydrochlorothiazide 25 mg and circadian blood pressure profile in patients with essential hypertension.
Coca A; Calvo C; Sobrino J; Gómez E; López-Paz JE; Sierra C; Bragulat E; de la Sierra A
Clin Ther; 2003 Nov; 25(11):2849-64. PubMed ID: 14693309
[TBL] [Abstract][Full Text] [Related]
15. Zofenopril plus hydrochlorothiazide and irbesartan plus hydrochlorothiazide in previously treated and uncontrolled diabetic and non-diabetic essential hypertensive patients.
Agabiti-Rosei E; Manolis A; Zava D; Omboni S;
Adv Ther; 2014 Feb; 31(2):217-33. PubMed ID: 24415271
[TBL] [Abstract][Full Text] [Related]
16. Effect of three months' treatment with irbesartan on blood and pulse pressure of hypertensive type 2 diabetic patients: open, observational study in 31,793 patients.
Strutz F; Bramlage P; Paar WD
Curr Med Res Opin; 2005 Sep; 21(9):1433-40. PubMed ID: 16197662
[TBL] [Abstract][Full Text] [Related]
17. Comparative efficacy of irbesartan/ hydrochlorothiazide and valsartan/hydrochlorothiazide combination in lowering blood pressure: a retrospective observational study in Oman.
Al Balushi KA; Habib JQ; Al-Zakwani I
Med Princ Pract; 2013; 22(3):265-9. PubMed ID: 23235349
[TBL] [Abstract][Full Text] [Related]
18. Initial combination therapy with irbesartan/hydrochlorothiazide for hypertension: an analysis of the relationship between baseline blood pressure and the need for combination therapy.
Franklin S; Lapuerta P; Cox D; Donovan M
J Clin Hypertens (Greenwich); 2007 Dec; 9(12 Suppl 5):15-22. PubMed ID: 18046108
[TBL] [Abstract][Full Text] [Related]
19. A multicenter, randomized, double-blind comparison of the efficacy and safety of irbesartan and enalapril in adults with mild to moderate essential hypertension, as assessed by ambulatory blood pressure monitoring: the MAPAVEL Study (Monitorización Ambulatoria Presión Arterial APROVEL).
Coca A; Calvo C; García-Puig J; Gil-Extremera B; Aguilera MT; de la Sierra A; Martín-Hidalgo A; Marín R;
Clin Ther; 2002 Jan; 24(1):126-38. PubMed ID: 11833827
[TBL] [Abstract][Full Text] [Related]
20. Significance of initial blood pressure and comorbidity for the efficacy of a fixed combination of an angiotensin receptor blocker and hydrochlorothiazide in clinical practice.
Schmieder RE; Schwertfeger M; Bramlage P
Vasc Health Risk Manag; 2009; 5():991-1000. PubMed ID: 19997579
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
